Profile data is unavailable for this security.
About the company
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche finished dosage formulations. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
- Revenue in INR (TTM)47.26bn
- Net income in INR5.11bn
- Incorporated1990
- Employees3.30k
- LocationStrides Pharma Science LtdStrides HouseBilekahalli, Bannerghatta RoadBANGALORE 560076IndiaIND
- Phone+91 8 067840000
- Fax+91 8 067840700
- Websitehttps://www.strides.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zota Health Care Ltd | 4.73bn | -726.58m | 47.30bn | 519.00 | -- | -- | -- | 10.00 | -23.98 | -23.98 | 157.24 | -- | -- | -- | -- | 9,108,992.00 | -- | -7.79 | -- | -10.57 | 57.22 | 42.02 | -15.34 | -8.01 | -- | -3.71 | -- | -- | 62.32 | 25.23 | -293.08 | -- | 49.40 | 0.00 |
| Supriya Lifescience Ltd | 7.35bn | 1.85bn | 55.29bn | 515.00 | 29.81 | -- | 26.17 | 7.52 | 23.05 | 23.05 | 91.47 | -- | -- | -- | -- | 14,280,700.00 | -- | 18.45 | -- | 21.63 | 72.33 | 59.62 | 25.19 | 25.45 | -- | 129.43 | -- | 3.59 | 22.11 | 17.45 | 57.80 | 20.69 | 45.94 | -- |
| F D C Ltd | 20.78bn | 2.17bn | 64.65bn | 6.86k | 29.83 | -- | 23.33 | 3.11 | 13.31 | 13.31 | 127.73 | -- | -- | -- | -- | 3,030,531.00 | -- | 11.35 | -- | 12.96 | 67.92 | 60.85 | 10.43 | 14.75 | -- | 47.92 | -- | 6.34 | 8.50 | 9.42 | -12.59 | 2.15 | 25.37 | -- |
| Shilpa Medicare Ltd | 13.42bn | 1.37bn | 66.44bn | 898.00 | 48.41 | 2.73 | 26.20 | 4.95 | 7.02 | 7.02 | 68.61 | 124.61 | 0.4058 | 0.9867 | 3.41 | 14,939,110.00 | 4.15 | 2.02 | 5.14 | 2.61 | 71.63 | 60.07 | 10.23 | 5.17 | 0.7867 | 4.09 | 0.1957 | 9.89 | 11.71 | 7.22 | 145.63 | -12.90 | 16.09 | -- |
| Aarti Pharmalabs Ltd | 19.06bn | 2.40bn | 69.30bn | 2.16k | 28.90 | 3.39 | 20.80 | 3.64 | 26.45 | 26.45 | 210.27 | 225.75 | 0.6309 | 1.39 | 4.22 | 8,812,209.00 | 7.94 | -- | 10.54 | -- | 51.04 | -- | 12.58 | -- | 0.8706 | 9.62 | 0.2435 | -- | 14.17 | -- | 25.59 | -- | -- | -- |
| Akums Drugs and Pharmaceuticals Ltd | 41.08bn | 3.17bn | 71.77bn | 7.54k | 22.64 | 2.28 | 14.87 | 1.75 | 20.71 | 20.71 | 268.25 | 205.66 | 0.8712 | 3.69 | 4.85 | 5,450,531.00 | 6.86 | -- | 8.82 | -- | 41.18 | -- | 7.87 | -- | 3.18 | 4.98 | 0.0277 | -- | -1.44 | -- | 8,481.07 | -- | -- | -- |
| Sudeep Pharma Ltd | 6.17bn | 1.68bn | 74.81bn | -- | 43.46 | -- | 40.73 | 12.13 | 15.24 | 15.24 | 55.94 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 63.01 | -- | 27.56 | -- | -- | 55.99 | -- | -- | 9.40 | -- | 4.19 | -- | -- | -- |
| Blue Jet Healthcare Ltd | 11.79bn | 3.52bn | 76.76bn | 491.00 | 21.77 | 6.11 | 20.54 | 6.51 | 20.32 | 20.32 | 68.01 | 72.39 | 0.8706 | 2.87 | 4.51 | 24,013,560.00 | 26.02 | -- | 31.72 | -- | 54.32 | -- | 29.89 | -- | 3.29 | 78.01 | 0.0162 | -- | 44.74 | -- | 86.38 | -- | -- | -- |
| Strides Pharma Science Ltd | 47.26bn | 5.11bn | 81.34bn | 3.30k | 15.90 | -- | 11.17 | 1.72 | 55.49 | 55.49 | 512.73 | -- | -- | -- | -- | 14,315,680.00 | -- | -0.6014 | -- | -1.09 | 59.34 | 50.33 | 11.23 | -1.06 | -- | 8.50 | -- | -- | 17.36 | 10.65 | 437.22 | 52.50 | 10.08 | -22.16 |
| Marksans Pharma Ltd | 28.03bn | 3.60bn | 84.74bn | 1.35k | 23.50 | -- | 18.47 | 3.02 | 7.96 | 7.96 | 61.92 | -- | -- | -- | -- | 20,780,450.00 | -- | 14.15 | -- | 17.41 | 56.77 | 51.56 | 12.90 | 14.58 | -- | 20.42 | -- | 7.77 | 20.46 | 18.25 | 21.32 | 26.60 | 23.73 | 51.57 |
| Viyash Scientific Ltd | 21.26bn | 768.08m | 89.43bn | 1.24k | 86.36 | -- | 44.42 | 4.21 | 2.37 | 2.37 | 70.40 | -- | -- | -- | -- | 17,086,170.00 | -- | 0.4014 | -- | 0.6553 | 51.15 | 42.16 | 4.52 | 0.4199 | -- | 3.92 | -- | 995.91 | 13.26 | 5.64 | 160.99 | -20.73 | -0.126 | -- |
| Procter & Gamble Health Ltd | 13.49bn | 2.93bn | 91.26bn | 1.33k | 31.13 | -- | 28.86 | 6.77 | 176.64 | 176.64 | 811.45 | -- | -- | -- | -- | 10,169,760.00 | -- | -- | -- | -- | 72.49 | -- | 21.76 | -- | -- | 806.81 | -- | -- | -- | -- | -- | -- | -- | -- |
| Jeena Sikho Lifecare Ltd | 6.19bn | 1.54bn | 91.79bn | 3.76k | 59.71 | 25.96 | 51.55 | 14.83 | 12.37 | 12.37 | 49.75 | 28.45 | 1.53 | 4.18 | 7.99 | 1,644,723.00 | 37.92 | 32.29 | 46.06 | 40.74 | 91.31 | 92.07 | 24.86 | 16.78 | 2.14 | 33.36 | 0.231 | -- | 44.59 | 37.80 | 31.10 | 73.77 | 47.62 | -- |
| Sanofi India Ltd | 19.33bn | 3.56bn | 94.26bn | 991.00 | 26.45 | -- | 23.94 | 4.88 | 154.71 | 154.71 | 839.09 | -- | -- | -- | -- | 19,500,500.00 | -- | 22.31 | -- | 31.44 | 51.42 | 54.10 | 18.44 | 21.53 | -- | 321.27 | -- | 132.73 | 0.8567 | -8.10 | -13.96 | -5.41 | -13.65 | 1.99 |
| Sanofi Consumer Healthcare India Ltd | 8.16bn | 2.18bn | 98.52bn | 583.00 | 45.21 | -- | 43.36 | 12.07 | 94.62 | 94.62 | 354.49 | -- | -- | -- | -- | 14,003,430.00 | -- | -- | -- | -- | 75.05 | -- | 26.69 | -- | -- | 143.16 | -- | -- | 30.45 | -- | 9.76 | -- | -- | -- |
| Corona Remedies Ltd | 13.44bn | 1.71bn | 99.91bn | 4.57k | 58.32 | -- | 47.81 | 7.44 | 28.01 | 28.01 | 219.70 | -- | -- | -- | -- | 2,980,876.00 | -- | -- | -- | -- | 81.28 | -- | 12.75 | -- | -- | 55.10 | -- | -- | 17.93 | -- | 65.11 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Strides Pharma Science Ltd's reporting currency: Indian Rupee INR
25.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Route One Investment Co. LPas of 30 Jun 2025 | 6.65m | 7.22% |
| quant Money Managers Ltd.as of 30 Jan 2026 | 4.98m | 5.40% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Dec 2025 | 2.51m | 2.73% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 2.50m | 2.71% |
| Bandhan AMC Ltd.as of 31 Dec 2025 | 1.46m | 1.59% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 1.46m | 1.58% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 1.34m | 1.45% |
| Life Insurance Corporation of India (Investment Portfolio)as of 24 Oct 2024 | 751.77k | 0.82% |
| Axis Asset Management Co. Ltd.as of 31 Dec 2025 | 735.03k | 0.80% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 681.55k | 0.74% |
More ▼
Data from 30 Jun 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
